TES / IPA Research Blend (15mg / 5mg)
For Research Use Only — Not for Human Use
Intended for laboratory research use only (e.g., analytical and in-vitro studies). Not for human use.
TES / IPA is a dual-peptide research blend combining a stabilized growth hormone-releasing hormone analog (TES) with a selective growth hormone secretagogue receptor peptide (Ipamorelin).
Researchers use this combination to study the interaction between GHRH-receptor signaling and ghrelin-receptor pathways under controlled laboratory conditions.
This compound is provided by GENIQ exclusively for scientific research and not for human or animal use.
$249.99
-
Official retailer -
Quality guaranteed
-
Free delivery from $99
-
Free returns is available
What Is TES / IPA?
TES / IPA is a synthetic peptide blend developed for research on pituitary signaling and growth hormone axis regulation.
TES is a 44-amino-acid GHRH analog stabilized with an N-terminal trans-3-hexenoyl group, which increases its resistance to enzymatic degradation in experimental systems. Ipamorelin is a pentapeptide that selectively engages the growth hormone secretagogue receptor (GHSR).
Researchers use this blend to investigate dual-pathway stimulation of somatotroph cells, hormone-pulse modeling, and downstream signaling cascades.
GENIQ provides this compound solely for controlled laboratory research, not for human or animal use.
Peptide Overview
This blend merges two peptides commonly used in endocrine signaling research:
TES:
A stabilized GHRH(1-44) analog studied for its impact on pituitary receptor activation, sustained GHRH-receptor signaling, and lipid-metabolism models.
Ipamorelin:
A selective GHSR (growth hormone secretagogue receptor) agonist investigated for its role in ghrelin-related cellular communication, receptor specificity, and downstream signaling mechanisms.
| Laboratory studies evaluate how this peptide combination may influence: |
| • Somatotroph cell signaling |
| • cAMP pathway activation |
| • GHRH-receptor and ghrelin-receptor co-stimulation |
| • Visceral adipose and lipid-metabolism models in preclinical settings |
| These findings are strictly from research environments. |
All findings remain limited to preclinical and in-vitro experimental environments.
History of TES / IPA
TES was developed as a stabilized analog of the full-length 44-amino-acid GHRH sequence, designed to resist rapid enzymatic cleavage while preserving native receptor interaction. It became one of the most extensively characterized GHRH analogs in the scientific literature.
Ipamorelin was introduced in the late 1990s as the first highly selective growth hormone secretagogue, showing minimal interaction with other pituitary hormones, which made it a valuable tool for isolating ghrelin-receptor pathways.
Researchers began pairing these peptides to investigate how simultaneous GHRH-receptor and GHSR activation behaves in experimental hormone-regulation studies. The combination remains of interest for in-vitro examination of pituitary dynamics and endocrine-signaling interactions.
Peptide Structure
TES Sequence:
(trans-3-Hexenoyl)-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH₂
Ipamorelin Sequence:
Aib-His-D-2-Nal-D-Phe-Lys-NH₂
Certificates of Analysis
TES / IPA (15mg / 5mg)
Research Findings
Research models analyzing the dual activity of TES and Ipamorelin commonly explore:
| • GHRH-receptor and GHSR pathway interactions: Studying combined receptor signaling when both pathways are activated. |
| • Pituitary-cell responsiveness: Examining how somatotrophs respond to dual-peptide stimulation. |
| • Intracellular messenger activity: Including cAMP activation, downstream gene-expression changes, and receptor-signal amplification. |
| • Lipid-metabolism modeling: Using TES to observe GHRH-analog effects on adipose-tissue signaling in preclinical models. |
| These data represent controlled in-vitro and preclinical studies, not clinical outcomes. |
These findings reflect laboratory experiments only and do not indicate clinical outcomes.
References
FAQ
Are GENIQ peptides pharmaceutical products?
No. They are not drugs, supplements, or therapeutic items. All compounds are provided strictly for laboratory research.
Who should purchase GENIQ research materials?
Qualified researchers, laboratories, and institutions working within applicable laws and regulations.
Do orders include COAs?
Yes. Each peptide includes a Certificate of Analysis confirming identity and purity testing when available for that lot.
What handling notes does GENIQ provide?
Only storage temperature and solvent-compatibility notes when listed on the product page. GENIQ does not provide guidance on preparation or application. Buyers follow their institution’s laboratory protocols.
Are these products for human use?
No. For Research Use Only — Not for Human Use. Not for human or animal consumption.
For Research Use Only — Not for Human Use
Sold exclusively as laboratory research materials. Not for human or animal consumption, clinical use, or household use.
Intended research use: Laboratory and in-vitro research, including analytical characterization and pathway / receptor-binding studies as applicable to this compound. Not for human consumption, clinical use, or diagnostic use on humans.
TES / IPA is a dual-peptide research blend combining a stabilized growth hormone-releasing hormone analog (TES) with a selective growth hormone secretagogue receptor peptide (Ipamorelin).
Researchers use this combination to study the interaction between GHRH-receptor signaling and ghrelin-receptor pathways under controlled laboratory conditions.
This compound is provided by GENIQ exclusively for scientific research and not for human or animal use.
RELATED PRODUCTS
BPC-157 / TB-500
Price range: $149.99 through $199.99
